Abstract
In recent years, a key issue in the management of patients with metastatic renal cell carcinoma (mRCC) has been the assessment of health-related quality of life (HRQoL), particularly following the introduction of targeted therapies that have brought significant improvements in progression-free survival and quality of life in these patients. HRQoL is becoming one of the main factors influencing choice of therapy, and HRQoL experienced during first-line treatment may affect the choice of the second-line therapy. Consequently, several trials have been conducted to evaluate the impact of approved targeted therapies for mRCC on HRQoL, and this measure is being introduced with increasing frequency in the trial design. With respect to agents used after progression on cytokines, sunitinib and temsirolimus have yielded better HRQoL scores, and sorafenib and pazopanib have shown stable HRQoL scores compared with placebo. Regarding targeted agents approved for patients who progress on a first-line tyrosine kinase inhibitor, everolimus has shown to delay and reduce the degree of Karnofsky performance status deterioration compared with placebo. Moreover, evidence obtained from these trials shows that tumor response and delay in disease progression affect HRQoL. In this article, we review the different HRQoL scales used to evaluate patients with mRCC along with the results obtained in clinical trials. Given that HRQoL is determined not only by treatment-related effects but also by mRCC symptoms and its clinical complications, the characteristics and appropriate treatment of the most commonly experienced symptoms, including anorexia, fatigue, pain, anemia, and venous thromboembolism, are also reviewed.
Similar content being viewed by others
References
Cella, D. (2011). Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. The Oncologist, 16(Suppl 2), 23–31.
Patil, S., Figlin, R. A., Hutson, T. E., Michaelson, M. D., Negrier, S., Kim, S. T., et al. (2009). Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts, 27(15S), 5042.
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579.
Cella, D., Hahn, E. A., & Dineen, K. (2002). Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Quality of Life Research, 11(3), 207–221.
Abel, E. J., Culp, S. H., Tannir, N. M., Tamboli, P., Matin, S. F., & Wood, C. G. (2011). Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. European Urology., 60, 1273–1279.
Cella, D., Yount, S., Du, H., Dhanda, R., Gondek, K., Langefeld, K., et al. (2006). Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). Journal of Supportive Oncology, 4(4), 191–199.
Cella, D., Yount, S., Brucker, P. S., Du, H., Bukowski, R., Vogelzang, N., et al. (2007). Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value in Health, 10(4), 285–293.
Rini, B. I., & Flaherty, K. (2008). Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urologic Oncology, 26(5), 543–549.
Gelber, R. D., Goldhirsch, A., & Cole, B. F. (1993). Evaluation of effectiveness: Q-TWiST. The International Breast Cancer Study Group. Cancer Treatment Reviews, 19(Suppl A), 73–84.
Glasziou, P. P., Simes, R. J., & Gelber, R. D. (1990). Quality adjusted survival analysis. Statistics in Medicine, 9(11), 1259–1276.
Bosaeus, I., Daneryd, P., Svanberg, E., & Lundholm, K. (2001). Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. International Journal of Cancer, 93(3), 380–383.
Argiles, J. M., Almendro, V., Busquets, S., & Lopez-Soriano, F. J. (2004). The pharmacological treatment of cachexia. Current Drug Targets, 5(3), 265–277.
Jatoi, A., Windschitl, H. E., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., Mailliard, J. A., et al. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology, 20(2), 567–573.
Jho, D., Babcock, T. A., Helton, W. S., & Espat, N. J. (2003). Omega-3 fatty acids: implications for the treatment of tumor-associated inflammation. American Surgeon, 69(1), 32–36.
Tisdale, M. J. (2003). The ‘cancer cachectic factor’. Supportive Care in Cancer, 11(2), 73–78.
Bruera, E., Strasser, F., Palmer, J. L., Willey, J., Calder, K., Amyotte, G., et al. (2003). Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. Journal of Clinical Oncology, 21(1), 129–134.
Grobbelaar, E. J., Owen, S., Torrance, A. D., & Wilson, J. A. (2004). Nutritional challenges in head and neck cancer. Clinical Otolaryngology and Allied Sciences, 29(4), 307–313.
Jatoi, A., Rowland, K., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., MacDonald, N., et al. (2004). An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology, 22(12), 2469–2476.
Afari, N., & Buchwald, D. (2003). Chronic fatigue syndrome: a review. The American Journal of Psychiatry, 160(2), 221–236.
Wyller, V. B. (2007). The chronic fatigue syndrome—an update. Acta Neurologica Scandinavica. Supplementum, 187, 7–14.
Bruera, E., & Neumann, C. M. (1998). Management of specific symptom complexes in patients receiving palliative care. Canadian Medical Association Journal, 158(13), 1717–1726.
Di Lorenzo, G., Buonerba, C., Federico, P., Rescigno, P., Milella, M., Ortega, C., et al. (2010). Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. European Urology, 58(6), 906–911.
Bruera, E., Brenneis, C., Michaud, M., & MacDonald, R. N. (1989). Influence of the pain and symptom control team (PSCT) on the patterns of treatment of pain and other symptoms in a cancer center. Journal of Pain and Symptom Management, 4(3), 112–116.
Cleeland, C. S., Gonin, R., Hatfield, A. K., Edmonson, J. H., Blum, R. H., Stewart, J. A., et al. (1994). Pain and its treatment in outpatients with metastatic cancer. The New England Journal of Medicine, 330(9), 592–596.
Leppert, W. (2011). Pain management in patients with cancer: focus on opioid analgesics. Current Pain and Headache Reports, 15(4), 271–279.
Henry, D. H. (2010). Parenteral iron therapy in cancer-associated anemia. Hematology American Society for Hematology Education Program, 2010, 351–356.
Beguin, Y. (1996). Erythropoietin and the anemia of cancer. Acta Clinica Belgica, 51(1), 36–52.
Escudier, B., & Kataja, V. (2010). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21(Suppl 5), v137–v139.
Blom, J. W., Doggen, C. J., Osanto, S., & Rosendaal, F. R. (2005). Malignancies, prothrombotic mutations, and the risk of venous thrombosis. Journal of the American Medical Association, 293(6), 715–722.
Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M., & Lyman, G. H. (2007). Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer, 110(10), 2339–2346.
Khorana, A. A., Francis, C. W., Culakova, E., & Lyman, G. H. (2005). Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer, 104(12), 2822–2829.
Sallah, S., Wan, J. Y., & Nguyen, N. P. (2002). Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thrombosis and Haemostasis, 87(4), 575–579.
Dvorak, H. F., Quay, S. C., Orenstein, N. S., Dvorak, A. M., Hahn, P., Bitzer, A. M., et al. (1981). Tumor shedding and coagulation. Science, 212(4497), 923–924.
Khorana, A. A., Ahrendt, S. A., Ryan, C. K., Francis, C. W., Hruban, R. H., Hu, Y. C., et al. (2007). Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clinical Cancer Research, 13(10), 2870–2875.
Tesselaar, M. E., Romijn, F. P., Van Der Linden, I. K., Prins, F. A., Bertina, R. M., & Osanto, S. (2007). Microparticle-associated tissue factor activity: a link between cancer and thrombosis? Journal of Thrombosis and Haemostasis, 5(3), 520–527.
Wahrenbrock, M., Borsig, L., Le, D., Varki, N., & Varki, A. (2003). Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. The Journal of Clinical Investigation, 112(6), 853–862.
Mismetti, P., Laporte-Simitsidis, S., Tardy, B., Cucherat, M., Buchmuller, A., Juillard-Delsart, D., et al. (2000). Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thrombosis and Haemostasis, 83(1), 14–19.
Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., et al. (2007). American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. Journal of Clinical Oncology, 25(34), 5490–5505.
Wagman, L. D., Baird, M. F., Bennett, C. L., Bockenstedt, P. L., Cataland, S. R., Fanikos, J., et al. (2006). Venous thromboembolic disease. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 4(9), 838–869.
Bianchi, M., Sun, M., Jeldres, C., Shariat, S. F., Trinh, Q. D., Briganti, A., et al. (2012). Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Annals of Oncology., 23, 973–980.
Coleman, R. E. (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews, 27(3), 165–176.
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., et al. (2008). Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals of Oncology, 19(3), 420–432.
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., et al. (2004). Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer, 100(12), 2613–2621.
Cella, D., Li, J. Z., Cappelleri, J. C., Bushmakin, A., Charbonneau, C., Kim, S. T., et al. (2008). Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Journal of Clinical Oncology, 26(22), 3763–3769.
Patil, S., Figlin, RA., Hutson, TE., Michaelson, D., Negrier, S., Kim, S.T., et al. TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-{alpha}). ASCO Meeting Abstracts. 28(15_suppl): 4594.
Bukowski, R., Cella, D., Gondek, K., & Escudier, B. (2007). Effects of Sorafenib on Symptoms and Quality of Life: Results From a Large Randomized Placebo-Controlled Study in Renal Cancer. American Journal of Clinical Oncology, 30(3), 220–227. doi:10.1097/01.coc.0000258732.80710.05.
Miyake, H., Kurahashi, T., Yamanaka, K., Kondo, Y., Takenaka, A., Inoue, T. A., et al. (2010). Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU International, 106(11), 1643–1647.
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., et al. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology, 28(6), 1061–1068.
Parasuraman, S., Hudes, G., Levy, D., Strahs, A., Moore, L., DeMarinis, R., et al. (2007). Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-{alpha} (IFN) or the combination of IFN+TEMSR. ASCO Meeting Abstracts, 25(18_suppl), 5049.
Yang, S., de Souza, P., Alemao, E., & Purvis, J. (2010). Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. British Journal of Cancer, 102(10), 1456–1460.
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 372(9637), 449–456.
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., et al. (2010). Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer, 116(18), 4256–4265.
Porta, C., Escudier, B., Hutson, T. E., Figlin, R. A., Calvo, E., Grunwald, V., et al. (2011). Analysis of the relationship between Karnofsky performance status (KPS) and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma (RCC). ASCO Meeting Abstracts, 29(15_suppl), 4610.
Acknowledgments
The authors acknowledge the support of Novartis Oncology, Spain, which has facilitated the necessary meetings to evaluate and discuss all the data presented in this review, and Ana Martín from HealthCo SL (Madrid, Spain) for assistance in the preparation of this manuscript.
Conflicts of interest
The authors declare that they do not have any conflict of interest that may inappropriately influence this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lambea, J., Hinojo, C., Lainez, N. et al. Quality of life and supportive care for patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 31 (Suppl 1), 33–39 (2012). https://doi.org/10.1007/s10555-012-9357-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-012-9357-9